1. A hospitalist is selecting carbapenem therapy for two patients simultaneously. Patient A is a 58-year-old woman being discharged on outpatient parenteral antibiotic therapy (OPAT) for a complicated urinary tract infection caused by an ESBL-producing Klebsiella pneumoniae susceptible to all carbapenems. Patient B is a 71-year-old man in the ICU with ventilator-associated pneumonia and prior respiratory cultures positive for Pseudomonas aeruginosa. The hospitalist considers ertapenem for both patients. Which of the following best describes why ertapenem is appropriate for Patient A but categorically inappropriate for Patient B?
A) Ertapenem is appropriate for Patient A because it achieves higher urinary concentrations than meropenem, making it superior for UTI regardless of the pathogen; it is inappropriate for Patient B because it requires cilastatin co-administration that is contraindicated in mechanically ventilated patients
B) Ertapenem is appropriate for Patient A because its long half-life and high protein binding support once-daily OPAT dosing and it covers ESBL-producing Enterobacteriaceae; it is inappropriate for Patient B because ertapenem lacks reliable activity against Pseudomonas aeruginosa, which is a plausible and high-risk pathogen in ventilator-associated pneumonia
C) Ertapenem is appropriate for Patient A because ESBL-producing organisms are susceptible to ertapenem's DHP-I-resistant formulation; it is inappropriate for Patient B because ertapenem's spectrum is limited to gram-positive organisms and would miss the gram-negative pathogens responsible for ventilator-associated pneumonia
D) Ertapenem is appropriate for Patient A because its monocyclic beta-lactam ring confers stability against ESBL hydrolysis that other carbapenems lack; it is inappropriate for Patient B because ertapenem does not penetrate into alveolar epithelial lining fluid at concentrations sufficient for gram-negative pneumonia
E) Ertapenem is appropriate for Patient A because once-daily dosing eliminates the need for renal dose adjustment in mild renal impairment; it is inappropriate for Patient B because the seizure risk of ertapenem is substantially higher than imipenem in ventilated patients with neurological monitoring lines
ANSWER: B
Rationale:
Two distinct pharmacological properties of ertapenem explain both the appropriate and inappropriate applications in these patients. First, ertapenem's pharmacokinetic profile — approximately 95% plasma protein binding producing a serum half-life of approximately 4 hours, compared to approximately 1 hour for imipenem and meropenem — supports once-daily IV or IM dosing that is practical for OPAT programs. Ertapenem is guideline-supported as definitive therapy for ESBL-producing Enterobacteriaceae infections including urinary tract infections, making it well-suited for Patient A. Second, ertapenem has a critical and well-characterized spectrum gap: it lacks reliable activity against Pseudomonas aeruginosa and Acinetobacter baumannii, organisms that are major pathogens in hospital-acquired and ventilator-associated pneumonia. A patient with prior Pseudomonas respiratory colonization is at high risk for Pseudomonas VAP; using ertapenem in this setting would leave the most likely pathogen entirely without coverage. Antipseudomonal carbapenems — meropenem, imipenem-cilastatin, or doripenem — are required for empiric therapy when Pseudomonas is a plausible pathogen.
Option A: Option A is incorrect; ertapenem does not achieve higher urinary concentrations than meropenem as a distinguishing pharmacokinetic feature, and ertapenem does not require cilastatin — it is formulated as a single agent because it is not hydrolyzed by DHP-I.
Option C: Option C is incorrect; ertapenem's spectrum covers gram-negative Enterobacteriaceae broadly, not gram-positive organisms selectively; the statement that it is limited to gram-positives is factually reversed.
Option D: Option D is incorrect; ertapenem does not have a monocyclic ring — it is a standard bicyclic carbapenem; the monocyclic ring is a feature of aztreonam.
Option E: Option E is incorrect; ertapenem has substantially lower seizure risk than imipenem and is not associated with a seizure risk that would contraindicate use in ventilated patients; seizure risk is not the reason ertapenem is avoided in Patient B.
2. A 74-year-old man with stage 4 chronic kidney disease (CrCl 18 mL/min), a prior ischemic stroke with residual cortical injury, and a history of one unprovoked seizure two years ago is started on imipenem-cilastatin for a complicated gram-negative intra-abdominal infection. On day 2 he develops a generalized tonic-clonic seizure. An intern asks why this patient was at such high risk. Which of the following best integrates the multiple risk factors that compounded his seizure risk with imipenem?
A) Renal impairment reduced cilastatin clearance, allowing cilastatin to accumulate and competitively displace GABA (gamma-aminobutyric acid) from its receptor; prior cortical injury lowered the threshold for cilastatin-mediated GABA displacement to produce clinical seizures
B) The prior stroke caused upregulation of voltage-gated sodium channels in perilesional cortex; imipenem activated these channels at the elevated plasma concentrations produced by reduced renal clearance, generating a focal seizure that secondarily generalized
C) Stage 4 CKD impaired hepatic conjugation of imipenem's active metabolite, causing accumulation of a pro-convulsant glucuronide; the prior seizure history indicated pre-existing epileptiform discharges that were unmasked by the metabolite at high plasma concentrations
D) The combination of a prior seizure history and cortical injury created a lowered baseline seizure threshold in the absence of any pharmacological contribution; imipenem itself does not cause seizures but inhibited the metabolism of the patient's existing anticonvulsant medication, reducing its efficacy
E) Imipenem's GABA-A (gamma-aminobutyric acid type A) receptor antagonism at the picrotoxin-binding site is amplified by three independent risk factors present in this patient: renal impairment reduces drug clearance causing imipenem accumulation and higher CNS drug exposure; pre-existing cortical injury from stroke disrupts the blood-brain barrier and raises baseline neuronal excitability; and prior seizure history indicates a lowered seizure threshold that makes the patient more vulnerable to any convulsant pharmacological stimulus
ANSWER: E
Rationale:
Imipenem's seizurogenic mechanism is GABA-A receptor antagonism at the picrotoxin-binding site within the chloride channel, reducing inhibitory neurotransmission and lowering the seizure threshold. This mechanism is not a binary on-off effect but is modulated by several independent patient-specific risk factors that compound multiplicatively. In this patient, three distinct risk factors converge: first, stage 4 chronic kidney disease (CrCl 18 mL/min) dramatically reduces imipenem's renal clearance, causing accumulation of imipenem and its ring-opened products to higher plasma and CNS concentrations than would occur with normal renal function — drug accumulation is the most consistently identified risk factor for imipenem-associated seizures; second, the prior ischemic stroke with residual cortical injury disrupts the blood-brain barrier at the lesion margin, allowing increased CNS drug penetration and altering the excitability of perilesional neurons; third, prior seizure history indicates that the patient's neuronal circuits already have a reduced seizure threshold, meaning that a given degree of GABA-A antagonism that would be subthreshold in a healthy brain is sufficient to trigger a clinical seizure. Understanding that these risk factors are multiplicative — not merely additive — explains why this patient seized on day 2 at a dose that might be tolerated in a younger patient with normal renal function and no CNS pathology.
Option A: Option A is incorrect; cilastatin does not accumulate to pharmacologically active levels relevant to GABA receptor function; it has no identified GABA receptor interaction, and seizure risk is attributable to imipenem (and its metabolites), not cilastatin.
Option B: Option B is incorrect; imipenem does not activate voltage-gated sodium channels; its CNS mechanism is GABAergic inhibition, not sodium channel activation.
Option C: Option C is incorrect; imipenem does not undergo hepatic conjugation to a pro-convulsant glucuronide; it is renally eliminated as the parent compound and ring-opened hydrolysis products, and glucuronide metabolite accumulation is not the recognized seizure mechanism.
Option D: Option D is incorrect; imipenem does cause seizures through its own direct GABA-A receptor pharmacology; it is not a drug interaction with anticonvulsant metabolism that explains this event.
3. A clinical microbiologist explains to a pharmacy resident why ceftazidime-avibactam is effective against KPC-producing CRE (carbapenem-resistant Enterobacteriaceae) but fails predictably against NDM-producing CRE. The explanation requires integrating knowledge of beta-lactamase enzyme class, catalytic mechanism, and inhibitor mechanism of action. Which of the following correctly links these concepts to explain the differential activity?
A) KPC is a class A serine beta-lactamase that uses a catalytic serine residue for hydrolysis; avibactam inhibits KPC by forming a reversible covalent carbamyl ester with this serine, blocking the enzyme's active site. NDM is a class B metallo-beta-lactamase that uses zinc-activated water for hydrolysis with no catalytic serine; avibactam's mechanism requires a serine target and therefore cannot engage the NDM active site, making ceftazidime-avibactam predictably inactive against NDM-producing organisms
B) KPC and NDM are both class A serine enzymes, but NDM carries a point mutation in the serine active site that creates steric clash with avibactam's DBO ring; ceftazidime-avibactam is therefore active against wild-type KPC but not against the structurally modified serine of NDM
C) KPC is inhibited by avibactam because KPC is a class C AmpC enzyme with a broad active site that accommodates the DBO ring of avibactam; NDM is a class A enzyme with a narrower active site that excludes avibactam, explaining the differential activity
D) Avibactam inhibits KPC through zinc chelation within KPC's binuclear zinc active site; NDM lacks zinc cofactors and uses a serine mechanism that avibactam's zinc-chelating chemistry cannot target, reversing the expected serine-versus-zinc distinction
E) Both KPC and NDM are serine enzymes but avibactam selectively inhibits KPC because KPC's class A active site generates a stable covalent adduct with avibactam; NDM's class A active site rapidly deacylates avibactam, releasing it before sustained inhibition can occur
ANSWER: A
Rationale:
The differential activity of ceftazidime-avibactam against KPC versus NDM is a direct consequence of enzyme class and inhibitor mechanism. KPC (Klebsiella pneumoniae carbapenemase) belongs to Ambler class A — a serine beta-lactamase that forms a covalent acyl-enzyme intermediate through its active-site serine residue during hydrolysis of the beta-lactam ring. Avibactam is a diazabicyclooctane (DBO) beta-lactamase inhibitor that forms a reversible covalent carbamyl ester with the catalytic serine of class A, C, and some class D serine beta-lactamases; it does not dissociate rapidly (the acylation is slow-reversible rather than fast-reversible), providing sustained enzyme inhibition at clinically achievable concentrations. NDM (New Delhi metallo-beta-lactamase) belongs to Ambler class B — a fundamentally different enzyme class in which one or two zinc ions activate a water molecule to serve as the nucleophile attacking the beta-lactam carbonyl. There is no catalytic serine in the NDM active site; avibactam has no mechanism of interaction with a zinc-coordinated water nucleophile and therefore provides no inhibitory activity against NDM whatsoever. This mechanistic mismatch is shared by vaborbactam and relebactam for the same reason.
Option B: Option B is incorrect; NDM is not a class A serine enzyme — it is a class B metallo-enzyme; the distinction is between enzyme classes, not a point mutation in a shared serine.
Option C: Option C is incorrect; KPC is a class A enzyme, not class C AmpC; the active site descriptions and class assignments are both wrong.
Option D: Option D is incorrect; avibactam does not function through zinc chelation — it forms a covalent carbamyl ester with a serine residue; KPC does not have a binuclear zinc active site; the mechanism assignments are completely inverted.
Option E: Option E is incorrect; NDM is not a class A enzyme and does not have a serine active site; the premise that both are serine enzymes is false.
4. A 62-year-old woman is in the ICU with bacteremia caused by a Klebsiella pneumoniae isolate confirmed to produce NDM (New Delhi metallo-beta-lactamase) by PCR. The isolate also co-produces a CTX-M (cefotaxime-Munich enzyme)-type ESBL on the same resistance plasmid. It is resistant to all carbapenems, ceftazidime-avibactam, and meropenem-vaborbactam. The infectious disease team selects aztreonam-avibactam. Integrating the properties of aztreonam, NDM, and avibactam, which of the following best explains why this combination is expected to be active against this isolate?
A) Aztreonam inhibits NDM directly by binding the enzyme's zinc cofactors through its sulfonic acid group, while avibactam provides complementary bactericidal activity through PBP3 binding; the combination achieves dual-target inhibition that neither agent achieves alone
B) Avibactam inhibits NDM at clinical concentrations, protecting aztreonam from NDM hydrolysis; once NDM is inhibited, aztreonam reaches its PBP3 target intact because the CTX-M ESBL co-produced by this isolate has low affinity for aztreonam and does not require inhibition
C) Aztreonam and avibactam both penetrate the outer membrane via TonB-dependent iron-uptake transporters in NDM-producing organisms; the siderophore-conjugated delivery of both agents to the periplasm bypasses the porin loss that causes resistance to standard carbapenems in this isolate
D) Aztreonam is intrinsically stable to NDM hydrolysis because the monocyclic beta-lactam ring is a poor substrate for zinc-dependent metallo-beta-lactamases; the co-produced CTX-M ESBL does hydrolyze aztreonam, but avibactam inhibits the CTX-M ESBL (a class A serine enzyme), protecting aztreonam so that its intrinsic NDM stability can translate into antibacterial activity
E) Avibactam directly inhibits both NDM and CTX-M ESBL simultaneously through a bifunctional DBO scaffold that contains one zinc-chelating arm targeting NDM and one serine-acylating arm targeting CTX-M; aztreonam then reaches its target unopposed by either enzyme
ANSWER: D
Rationale:
The pharmacological rationale for aztreonam-avibactam against NDM-producing organisms integrates three distinct drug and enzyme properties. First, aztreonam possesses intrinsic resistance to hydrolysis by class B metallo-beta-lactamases including NDM, because the monocyclic beta-lactam ring of aztreonam is a poor substrate for the zinc-activated water hydrolytic mechanism of class B enzymes — this property is unique to the monobactam class and distinguishes aztreonam from all other beta-lactams, all of which are NDM substrates. Second, NDM-producing clinical isolates almost universally co-produce serine beta-lactamases (in this case a CTX-M-type ESBL, a class A serine enzyme) encoded on the same resistance plasmid; CTX-M ESBLs efficiently hydrolyze aztreonam, which is why aztreonam monotherapy fails against ESBL-producing organisms despite in vitro susceptibility at standard inocula. Third, avibactam is a class A, C, and some class D serine beta-lactamase inhibitor that forms a reversible covalent carbamylation with the CTX-M catalytic serine, inactivating the co-produced enzyme that would otherwise destroy aztreonam. The result: avibactam removes the ESBL threat to aztreonam, leaving aztreonam to exploit its intrinsic NDM stability and reach PBP3 intact.
Option A: Option A is incorrect; aztreonam does not inhibit NDM through zinc binding — aztreonam is simply not a good NDM substrate; the sulfonic acid group does not interact with NDM's zinc cofactors.
Option B: Option B is incorrect; avibactam does not inhibit NDM — it has no mechanism of action against class B metallo-beta-lactamases; the statement that "NDM is inhibited by avibactam" is factually false.
Option C: Option C is incorrect; aztreonam is not a siderophore conjugate and does not use TonB-dependent transporters; siderophore-mediated uptake is the mechanism of cefiderocol, not aztreonam.
Option E: Option E is incorrect; avibactam is not bifunctional with a zinc-chelating arm — it is a serine-only inhibitor with no zinc-chelating chemical moiety; simultaneous NDM and CTX-M inhibition by avibactam is not mechanistically possible.
5. An infectious disease fellow is comparing meropenem-vaborbactam and ceftazidime-avibactam for treatment of confirmed KPC-CRE bacteremia. The attending asks the fellow to integrate vaborbactam's mechanism, its carbapenemase spectrum, and the available clinical trial evidence. Which of the following best integrates these elements?
A) Vaborbactam is a DBO (diazabicyclooctane) inhibitor with the same mechanism as avibactam; both inhibit KPC, NDM, and OXA-48 equivalently, and the TANGO II trial (a randomized controlled trial of meropenem-vaborbactam versus best available therapy for carbapenem-resistant infections) demonstrated that meropenem-vaborbactam was non-inferior to ceftazidime-avibactam for all CRE genotypes
B) Vaborbactam is a boronic acid inhibitor that covers KPC and OXA-48 but not AmpC or NDM; the TANGO II trial showed non-inferiority to best available therapy but failed to demonstrate superiority, limiting its preferred use to situations where ceftazidime-avibactam is unavailable
C) Vaborbactam is a cyclic boronic acid inhibitor that forms a reversible covalent tetrahedral adduct with the catalytic serine of class A (KPC) and class C (AmpC) serine beta-lactamases; it does not inhibit class B NDM because NDM lacks a catalytic serine; the TANGO II trial demonstrated superior 28-day outcomes with meropenem-vaborbactam over best available therapy specifically for KPC-CRE infections
D) Vaborbactam is a cyclic boronic acid inhibitor that covers KPC, NDM, and VIM because its boronic acid moiety chelates the zinc cofactors of class B enzymes in addition to acylating the serine of class A enzymes; the TANGO II trial confirmed this broad spectrum in a phase 3 randomized trial
E) Vaborbactam inhibits class A and class B enzymes but not class C AmpC, because AmpC's narrow active site excludes the cyclic boronic acid scaffold; the TANGO II trial was conducted exclusively in KPC-CRE urinary tract infections and the results cannot be extrapolated to bacteremia
ANSWER: C
Rationale:
Vaborbactam is a cyclic boronic acid beta-lactamase inhibitor that exerts its effect by forming a reversible covalent tetrahedral boronate ester with the active-site serine of serine beta-lactamases. Its inhibitory spectrum covers class A enzymes (KPC and some CTX-M-type ESBLs) and class C AmpC cephalosporinases; it does not inhibit class B metallo-beta-lactamases (NDM, VIM, IMP) because these enzymes lack a catalytic serine and use zinc-activated water as their nucleophile — vaborbactam's boronic acid mechanism has no interaction with the zinc-dependent active site. Class D OXA-48 inhibition by vaborbactam is limited compared to avibactam, which inhibits OXA-48 more reliably. The TANGO II trial (a randomized, multicenter, open-label trial) compared meropenem-vaborbactam to best available therapy in patients with serious carbapenem-resistant gram-negative infections including KPC-CRE; it demonstrated superior 28-day all-cause mortality and higher clinical cure rates with meropenem-vaborbactam for KPC-CRE infections — one of the first prospective randomized trials to show outcome superiority with a novel CRE-directed regimen.
Option A: Option A is incorrect; vaborbactam is a boronic acid inhibitor, not a DBO inhibitor; it does not cover NDM or OXA-48 reliably; and the TANGO II trial compared meropenem-vaborbactam to best available therapy, not to ceftazidime-avibactam directly.
Option B: Option B is incorrect; vaborbactam covers AmpC (class C) in addition to KPC; OXA-48 coverage is limited; and the TANGO II trial demonstrated superiority, not non-inferiority, of meropenem-vaborbactam over best available therapy for KPC-CRE.
Option D: Option D is incorrect; vaborbactam does not inhibit NDM or VIM — it has no zinc-chelating activity; the boronic acid mechanism is serine-dependent only.
Option E: Option E is incorrect; vaborbactam does inhibit AmpC (class C) — the active site accommodates the boronic acid scaffold; and the TANGO II trial included bacteremia and other serious infections, not only urinary tract infections (the TANGO I trial focused on complicated UTIs).
6. A Klebsiella pneumoniae blood culture isolate is found to be resistant to all tested carbapenems but negative on a comprehensive carbapenemase PCR panel (KPC, NDM, VIM, IMP, OXA-48 all negative). Whole-genome sequencing reveals loss-of-function mutations in OmpK35 and OmpK36 and overexpression of a chromosomal CTX-M-15 ESBL. Susceptibility testing shows the isolate is susceptible to ceftazidime-avibactam and meropenem-vaborbactam. Integrating the resistance mechanism with the inhibitor spectra of the available agents, which of the following best explains why ceftazidime-avibactam and meropenem-vaborbactam are both active against this isolate despite the lack of a carbapenemase?
A) Ceftazidime-avibactam and meropenem-vaborbactam are active because both avibactam and vaborbactam inhibit NDM-like enzymes that the standard PCR panel missed; the isolate's apparent PCR negativity reflects a variant NDM gene not covered by standard probes
B) The isolate's carbapenem resistance is mediated by OmpK35/OmpK36 porin loss combined with CTX-M-15 ESBL overexpression — mechanisms that do not involve a carbapenemase; avibactam and vaborbactam both inhibit CTX-M-15 (a class A serine ESBL), eliminating the enzymatic component of resistance; carbapenem entry is partially restored when the enzymatic hydrolysis component is eliminated, and ceftazidime (a cephalosporin) and meropenem (a carbapenem) reach their PBP targets more effectively once the ESBL is inhibited
C) Avibactam and vaborbactam are active because both compounds directly restore OmpK35 and OmpK36 porin expression by inhibiting the regulatory repressor protein that silenced these genes in response to carbapenem exposure; restored porin expression allows ceftazidime and meropenem to re-enter the periplasm normally
D) Ceftazidime-avibactam and meropenem-vaborbactam are active because the beta-lactam partners (ceftazidime and meropenem) are inherently resistant to ESBL hydrolysis at the concentrations achieved with standard IV dosing, regardless of whether an inhibitor is present; the inhibitors provide no meaningful additional contribution in non-carbapenemase CRE
E) Both combinations are active because avibactam and vaborbactam inhibit the chromosomal AmpC that is the primary driver of carbapenem resistance in Klebsiella pneumoniae OmpK35/OmpK36-deficient strains; CTX-M-15 is a bystander enzyme that plays no role in carbapenem resistance in this organism
ANSWER: B
Rationale:
Non-carbapenemase-mediated carbapenem resistance in Klebsiella pneumoniae arises from the synergy of two mechanisms: porin loss (OmpK35/OmpK36 mutations reduce carbapenem influx) combined with ESBL or AmpC overexpression (enzymatic hydrolysis of the reduced drug that does enter the periplasm). Neither mechanism alone produces high-level resistance; together they create a carbapenem MIC above the susceptibility breakpoint without any carbapenemase. Critically, the ESBL component is a class A serine enzyme (CTX-M-15 in this case) that is inhibited by both avibactam (a DBO inhibitor of class A/C/D serine beta-lactamases) and vaborbactam (a boronic acid inhibitor of class A KPC and class C AmpC — and notably CTX-M ESBLs fall within class A). By inhibiting the CTX-M-15 ESBL, both combinations remove the enzymatic hydrolysis component of resistance; the remaining porin-loss component alone produces only intermediate-level reduction in carbapenem entry, which the higher concentrations of ceftazidime and meropenem in standard dosing can overcome. This explains why non-carbapenemase CRE often remains susceptible to beta-lactam/inhibitor combinations even when carbapenem MICs are elevated.
Option A: Option A is incorrect; the PCR-negative result in this case reflects genuine absence of carbapenemase genes, not a detection gap; the resistance mechanism is established as porin loss plus ESBL, not an occult NDM variant.
Option C: Option C is incorrect; avibactam and vaborbactam are beta-lactamase inhibitors that act on enzymes — they have no mechanism of restoring porin expression or interacting with regulatory repressor proteins.
Option D: Option D is incorrect; ceftazidime and meropenem are not inherently ESBL-resistant at standard dosing concentrations — in fact, ceftazidime is an excellent ESBL substrate, and meropenem is hydrolyzed by ESBL at high inocula; the inhibitors play an essential role.
Option E: Option E is incorrect; CTX-M-15 is a class A enzyme (not a bystander) that contributes directly to carbapenem resistance in combination with porin loss; while AmpC could also contribute, CTX-M-15 is specifically identified in this isolate as the overexpressed enzyme.
7. An infectious disease fellow presents a case of carbapenem-resistant Acinetobacter baumannii (CRAB) pneumonia and proposes cefiderocol as first-line monotherapy, citing its siderophore mechanism and broad activity against carbapenem-resistant pathogens. The attending asks the fellow to integrate cefiderocol's mechanism of outer membrane penetration, its target, and the relevant clinical trial finding before finalizing the recommendation. Which of the following best integrates these elements?
A) Cefiderocol uses a catecholate siderophore moiety to hijack bacterial TonB-dependent iron-uptake transporters for active outer membrane penetration, bypassing OprD and standard porins; once in the periplasm it binds PBP3 and is stable to all beta-lactamase classes including NDM and OXA-23; however, the CREDIBLE-CR trial (a non-randomized descriptive phase 3 trial comparing cefiderocol to best available therapy in carbapenem-resistant infections) reported numerically higher all-cause mortality in the cefiderocol arm within the Acinetobacter baumannii subgroup, introducing clinical caution about its use as first-line monotherapy for CRAB
B) Cefiderocol penetrates the outer membrane via OprD porin in a concentration-dependent manner that is not shared by other cephalosporins; in the CREDIBLE-CR trial, cefiderocol demonstrated superior survival compared to best available therapy in the Acinetobacter subgroup, supporting its use as the preferred first-line agent for all CRAB infections regardless of severity
C) Cefiderocol's siderophore moiety delivers the drug to the outer membrane surface where it binds to LPS (lipopolysaccharide) and triggers autolytic disruption of the cell wall; in the CREDIBLE-CR trial, cefiderocol achieved 100% microbiological eradication in the Acinetobacter subgroup but showed no mortality benefit, leading to its approval being restricted to microbiological endpoints only
D) Cefiderocol achieves outer membrane penetration via passive diffusion through lipid-disordered regions created by OXA-23-mediated LPS remodeling in CRAB strains; the CREDIBLE-CR trial showed that cefiderocol was non-inferior to colistin in the Acinetobacter subgroup, with a favorable safety profile that established it as the preferred alternative to polymyxins for CRAB
E) Cefiderocol is transported into the periplasm by the AcrAB-TolC efflux pump operating in reverse under iron-depleted conditions; the CREDIBLE-CR trial was terminated early in the Acinetobacter subgroup due to excess nephrotoxicity in the cefiderocol arm, contraindicating its use in patients with pre-existing renal impairment
ANSWER: A
Rationale:
Integrating cefiderocol's three key properties reveals both its therapeutic rationale and its clinical limitations for CRAB. First, the mechanism of outer membrane penetration: cefiderocol is conjugated to a catecholate siderophore that chelates ferric iron (Fe³⁺); the resulting ferric-cefiderocol complex is recognized and actively transported across the outer membrane by TonB-dependent outer membrane transporters — the same system bacteria use to acquire iron from the environment. This mechanism is entirely independent of OprD, OmpF, OmpC, and other standard diffusion porins, allowing cefiderocol to penetrate organisms with extensive porin loss. Second, the intracellular target: once in the periplasm, cefiderocol binds PBP3 (the cell division transpeptidase) with high affinity and is highly stable to hydrolysis by all known beta-lactamase classes including NDM (class B) and OXA-23 (class D), a particularly important property for CRAB therapy. Third, the clinical trial evidence: the CREDIBLE-CR trial (Bassetti et al., Lancet Infectious Diseases, 2021) was a non-randomized open-label descriptive trial. Despite cefiderocol's microbiological activity, the trial reported numerically higher all-cause mortality in the cefiderocol arm versus best available therapy specifically in the Acinetobacter baumannii patient subset. This unexpected and unexplained mortality signal has led to clinical caution about using cefiderocol as first-line monotherapy for CRAB; sulbactam-durlobactam is now the first FDA-approved targeted therapy for CRAB infections.
Option B: Option B is incorrect; cefiderocol does not use OprD for penetration — that is the carbapenem porin pathway that CRAB has lost; cefiderocol specifically bypasses OprD; and the CREDIBLE-CR trial showed higher, not lower, mortality in the Acinetobacter subgroup with cefiderocol.
Option C: Option C is incorrect; cefiderocol's siderophore does not bind LPS or trigger autolytic disruption; the drug enters the periplasm via TonB-dependent active transport and then binds PBP3 as a conventional beta-lactam.
Option D: Option D is incorrect; cefiderocol penetrates via TonB-dependent transporters, not via passive diffusion through OXA-23-modified LPS regions; and the CREDIBLE-CR Acinetobacter finding was a mortality signal, not non-inferiority to colistin.
Option E: Option E is incorrect; AcrAB-TolC is an efflux pump that exports drugs, not imports them; cefiderocol uses TonB-dependent import transporters; and the CREDIBLE-CR trial was not terminated early for nephrotoxicity.
8. A pharmacist is explaining to a medical student why sulbactam-durlobactam (Xacduro) requires both components for activity against carbapenem-resistant Acinetobacter baumannii (CRAB). The student asks why sulbactam alone is insufficient and why durlobactam was added. Integrating sulbactam's antibacterial mechanism and its enzymatic vulnerability with durlobactam's inhibitor class and target, which of the following best explains the rationale?
A) Sulbactam alone is insufficient because it cannot penetrate the outer membrane of CRAB without the assistance of durlobactam, which functions as a membrane permeabilizer that disrupts lipopolysaccharide and opens non-specific channels through which sulbactam enters the periplasm to reach its PBP targets
B) Sulbactam alone is insufficient because it has no direct antibacterial activity against Acinetobacter; it functions solely as a beta-lactamase inhibitor protecting a partner carbapenem; durlobactam is added as the active antibacterial agent that binds PBP2 with high affinity, providing the actual bactericidal killing against CRAB
C) Sulbactam alone is insufficient because it is rapidly effluxed from the Acinetobacter periplasm by the AdeABC efflux pump; durlobactam inhibits the AdeABC pump, allowing sulbactam to accumulate in the periplasm to concentrations sufficient for PBP1 and PBP3 binding
D) Sulbactam has intrinsic antibacterial activity against Acinetobacter baumannii through direct PBP1 and PBP3 binding, but CRAB strains produce OXA-type carbapenemases (primarily OXA-23 and OXA-58 class D serine beta-lactamases) that hydrolyze sulbactam, rendering it inactive as monotherapy; durlobactam is a DBO (diazabicyclooctane) inhibitor that inhibits these class D serine enzymes, protecting sulbactam from hydrolysis and restoring its PBP-mediated antibacterial activity
E) Sulbactam alone is insufficient because PBP1 and PBP3 in CRAB strains have acquired mutations that reduce sulbactam binding affinity; durlobactam reverses these mutations by acting as a pharmacological chaperone that restores the wild-type PBP conformation, enabling sulbactam to bind its targets at clinically achievable concentrations
ANSWER: D
Rationale:
The sulbactam-durlobactam combination is built on sulbactam's unique property among beta-lactamase inhibitors: intrinsic antibacterial activity against Acinetobacter baumannii through direct, high-affinity binding to PBP1 and PBP3. All other clinically used beta-lactamase inhibitors (clavulanate, tazobactam, avibactam, vaborbactam) have no direct antibacterial activity — they are pharmacologically inert except as enzyme inhibitors. Sulbactam's PBP binding makes it a therapeutic agent in its own right against Acinetobacter, not merely a protector of a partner beta-lactam. However, CRAB strains have evolved resistance to sulbactam by producing OXA-type carbapenemases — primarily OXA-23 and OXA-58, which are class D serine beta-lactamases that hydrolyze sulbactam before it can accumulate to PBP-binding concentrations in the periplasm. Durlobactam is a diazabicyclooctane (DBO) inhibitor structurally related to avibactam and relebactam; like those agents, it inhibits class A, class C, and class D serine beta-lactamases through reversible covalent carbamylation. By inhibiting OXA-23 and OXA-58, durlobactam eliminates the enzymatic threat to sulbactam, allowing sulbactam to persist in the periplasm at concentrations sufficient for PBP1 and PBP3 engagement.
Option A: Option A is incorrect; durlobactam is a beta-lactamase inhibitor, not a membrane permeabilizer; it acts on OXA-type enzymes intracellularly, not on lipopolysaccharide externally, and sulbactam can penetrate the Acinetobacter outer membrane independently.
Option B: Option B is incorrect; sulbactam does have direct antibacterial activity against Acinetobacter through PBP binding — this is the defining feature that distinguishes it from other beta-lactamase inhibitors; durlobactam does not itself bind PBP2 as an antibacterial agent.
Option C: Option C is incorrect; the mechanism of sulbactam's failure against CRAB is enzymatic hydrolysis by OXA-type carbapenemases, not AdeABC efflux; durlobactam inhibits serine beta-lactamases, not efflux pumps.
Option E: Option E is incorrect; CRAB resistance to sulbactam is not mediated by PBP mutations reducing binding affinity (that mechanism is characteristic of methicillin resistance in staphylococci); the dominant resistance mechanism is OXA carbapenemase hydrolysis of sulbactam, and durlobactam addresses this enzymatic mechanism.
9. A 47-year-old man with a documented anaphylactic reaction to penicillin undergoes emergency surgery for a perforated sigmoid colon with fecal peritonitis. The surgical team proposes aztreonam monotherapy to avoid all beta-lactam cross-reactivity risk. An infectious disease consultant objects. Integrating aztreonam's spectrum with the microbiology of fecal peritonitis, which of the following best explains why aztreonam monotherapy is inadequate and what additional coverage is required?
A) Aztreonam monotherapy is inadequate because aztreonam has significant cross-reactivity with penicillin through shared R1 side chain epitopes, making its use in penicillin-allergic patients as unsafe as ampicillin; an alternative non-beta-lactam regimen must be used for this patient
B) Aztreonam monotherapy is inadequate because aztreonam does not cover Pseudomonas aeruginosa, which is the most common pathogen in fecal peritonitis; aztreonam must be combined with an antipseudomonal fluoroquinolone to provide adequate gram-negative coverage for this infection
C) Aztreonam monotherapy is inadequate because aztreonam is rapidly inactivated by the high beta-lactamase burden in the polymicrobial peritoneal environment; a beta-lactamase inhibitor such as avibactam must be co-administered to preserve aztreonam's activity against the Enterobacteriaceae present in bowel flora
D) Aztreonam monotherapy is inadequate because aztreonam does not penetrate into abscesses or necrotic tissue; it must be combined with a drug with demonstrated penetration into anaerobic microenvironments such as metronidazole, which also provides direct bactericidal activity against aerobic gram-negatives
E) Aztreonam monotherapy is inadequate because aztreonam covers aerobic gram-negative bacilli only, leaving gram-positive organisms (including Enterococcus species and streptococci) and obligate anaerobes (including Bacteroides fragilis, the dominant anaerobe in colonic flora) without coverage; aztreonam must be combined with at minimum an anti-anaerobic agent (such as metronidazole) and an agent covering gram-positive organisms to provide adequate spectrum for polymicrobial fecal peritonitis
ANSWER: E
Rationale:
Fecal peritonitis from colonic perforation produces a classic polymicrobial infection involving three microbial groups: aerobic gram-negative Enterobacteriaceae (E. coli, Klebsiella), gram-positive cocci (Enterococcus faecalis, streptococci, occasionally staphylococci), and obligate anaerobes dominated by the Bacteroides fragilis group. Aztreonam's spectrum is restricted exclusively to aerobic gram-negative bacilli through its high-affinity binding to PBP3 of gram-negative organisms; it has absolutely no activity against gram-positive organisms (which lack the outer membrane required for aztreonam to reach its target and have PBP3 homologs with negligible aztreonam affinity) and no activity against anaerobes (which similarly lack the outer membrane and relevant PBP targets). Using aztreonam as monotherapy for fecal peritonitis would treat only one of three microbial groups present. Standard management in a penicillin-allergic patient requires coverage of all three groups; a practical approach combines aztreonam (gram-negative coverage) with metronidazole (anaerobic coverage) and an agent such as vancomycin or linezolid for gram-positive coverage if Enterococcus is a concern, or relies on aztreonam-metronidazole if gram-positive risk is low. Note that aztreonam is safe in this penicillin-allergic patient — its monocyclic ring structure carries negligible cross-reactivity with penicillins.
Option A: Option A is incorrect; aztreonam does not cross-react with penicillin through R1 side chain epitopes in a clinically meaningful way; its monocyclic structure eliminates the bicyclic ring epitopes responsible for penicillin IgE sensitization, and it is safe in penicillin-allergic patients.
Option B: Option B is incorrect; Pseudomonas aeruginosa is not a dominant pathogen in community-acquired fecal peritonitis from colonic perforation; the critical coverage gaps are gram-positives and anaerobes, not Pseudomonas.
Option C: Option C is incorrect; aztreonam's failure in this scenario is a spectrum gap (wrong organisms), not enzymatic inactivation; the peritoneal beta-lactamase burden does not make aztreonam monotherapy pharmacologically inadequate against susceptible organisms.
Option D: Option D is incorrect; aztreonam does penetrate into peritoneal fluid and achieves adequate tissue concentrations; metronidazole provides anaerobic coverage but has no activity against aerobic gram-negatives, so this combination would not address the gram-positive gap either.
10. A pharmacist is asked to justify why ertapenem's pharmacokinetics support once-daily dosing for ESBL-producing Enterobacteriaceae infections while meropenem requires every-8-hour dosing for the same organisms. The pharmacist must integrate ertapenem's protein binding, half-life, and the pharmacodynamic target of beta-lactam antibiotics. Which of the following best integrates these elements?
A) Ertapenem's once-daily dosing is justified by its concentration-dependent bactericidal pharmacodynamics; because ertapenem's Cmax (peak plasma concentration) after a 1 g once-daily dose exceeds the MIC (minimum inhibitory concentration) of ESBL-producing organisms by more than 10-fold, a single daily dose achieves the pharmacodynamic target that meropenem's smaller every-8-hour doses cannot match
B) Ertapenem's once-daily dosing is possible because it undergoes extensive hepatic metabolism to an active metabolite with a 12-hour half-life, effectively extending the dosing interval; meropenem is renally eliminated without active metabolite formation, requiring more frequent dosing to maintain adequate tissue concentrations
C) Ertapenem's approximately 95% plasma protein binding limits its volume of distribution and slows renal clearance of the free fraction, producing a serum half-life of approximately 4 hours compared to approximately 1 hour for meropenem; because beta-lactam bactericidal activity is time-dependent (efficacy determined by the proportion of the dosing interval that free drug concentration exceeds the MIC), the prolonged half-life of ertapenem sustains adequate free drug time above MIC over 24 hours at the standard 1 g once-daily dose
D) Ertapenem requires once-daily dosing rather than more frequent dosing because its high protein binding prevents glomerular filtration, forcing exclusive tubular secretion that produces a bell-shaped plasma concentration-time curve incompatible with the steady-state kinetics required for time-above-MIC pharmacodynamics with every-8-hour dosing
E) Ertapenem is dosed once daily because its post-antibiotic effect against ESBL-producing Enterobacteriaceae exceeds 18 hours, allowing the drug to suppress bacterial regrowth long after plasma concentrations fall below the MIC; meropenem's shorter post-antibiotic effect of approximately 2 hours necessitates more frequent dosing to prevent bacterial regrowth between doses
ANSWER: C
Rationale:
Beta-lactam antibiotics, including carbapenems, exhibit time-dependent (not concentration-dependent) bactericidal pharmacodynamics: the pharmacodynamic target is the percentage of the dosing interval (%T) during which free (unbound) drug concentration remains above the MIC of the pathogen. Increasing the dose beyond what is needed to exceed the MIC provides no additional killing; what matters is sustaining free drug concentration above the MIC for a sufficient proportion of the dosing interval (typically ≥40% for bacteriostatic effect, ≥60–70% for bactericidal effect against gram-negatives). Ertapenem's approximately 95% plasma protein binding is the pharmacokinetic basis for its extended half-life: because only the free (unbound ~5%) fraction is subject to glomerular filtration and renal clearance, the overall drug elimination is slowed, producing a serum half-life of approximately 4 hours. By comparison, meropenem is approximately 2% protein-bound; virtually all meropenem in plasma is free and subject to rapid renal clearance, producing a half-life of approximately 1 hour. Ertapenem's 4-hour half-life means that free drug concentrations decline slowly enough to remain above the MIC of susceptible ESBL-producing Enterobacteriaceae throughout a 24-hour interval at the standard 1 g dose, meeting the time-above-MIC pharmacodynamic target.
Option A: Option A is incorrect; beta-lactam killing is time-dependent, not concentration-dependent — peak concentration exceeding MIC by any multiple does not justify once-daily dosing; what matters is sustained time above MIC throughout the dosing interval.
Option B: Option B is incorrect; ertapenem is primarily renally eliminated as the parent compound and does not undergo hepatic metabolism to a pharmacologically active metabolite with a 12-hour half-life.
Option D: Option D is incorrect; high protein binding does not force exclusive tubular secretion or produce a bell-shaped concentration curve; the mechanism is straightforward — high binding slows the rate of glomerular filtration of the free fraction, extending the half-life.
Option E: Option E is incorrect; beta-lactams as a class have minimal post-antibiotic effects against gram-negative organisms; an 18-hour PAE for ertapenem against Enterobacteriaceae is not supported by pharmacokinetic-pharmacodynamic data, and PAE is not the mechanism underlying once-daily dosing justification.
11. An infectious disease consultant is selecting therapy for a 55-year-old man with ventilator-associated pneumonia caused by a Pseudomonas aeruginosa isolate that is resistant to piperacillin-tazobactam, ceftazidime, and all carbapenems. Susceptibility testing shows the isolate is susceptible to imipenem-relebactam but resistant to meropenem-vaborbactam. Whole-genome sequencing reveals the resistance mechanism is AmpC overexpression combined with OprD porin loss, without any carbapenemase. Integrating relebactam's enzyme inhibitory spectrum with AmpC's role in Pseudomonas carbapenem resistance, which of the following best explains the differential susceptibility to these two combinations?
A) Imipenem-relebactam is active because relebactam inhibits OprD porin synthesis in Pseudomonas, restoring imipenem's ability to enter the periplasm via the normal carbapenem diffusion channel; meropenem-vaborbactam is inactive because vaborbactam lacks the ability to modulate porin expression in Pseudomonas aeruginosa
B) Imipenem-relebactam is active because imipenem binds PBP2 in Pseudomonas with higher affinity than meropenem, so even when AmpC is overexpressed, sufficient imipenem survives hydrolysis to achieve bactericidal PBP2 occupancy; meropenem is inactive against this isolate because its lower PBP2 affinity makes it fully dependent on AmpC inhibition
C) Imipenem-relebactam is active because relebactam chelates the zinc cofactors of Pseudomonas AmpC, irreversibly inactivating the enzyme; meropenem-vaborbactam is inactive because vaborbactam's boronic acid scaffold cannot interact with zinc-containing AmpC variants expressed in Pseudomonas aeruginosa clinical isolates
D) Relebactam is a DBO inhibitor that inhibits class C AmpC cephalosporinases in addition to class A KPC-type enzymes; by inhibiting the overexpressed chromosomal AmpC in this Pseudomonas isolate, relebactam reduces the enzymatic hydrolysis that would otherwise inactivate imipenem before it reaches its PBP targets; vaborbactam also inhibits AmpC but has substantially less established activity against difficult-to-treat Pseudomonas aeruginosa in clinical data, while relebactam's combination with imipenem has demonstrated activity against MDR Pseudomonas with AmpC-mediated resistance
E) Imipenem-relebactam is active because relebactam inhibits the MexAB-OprM efflux pump that is responsible for imipenem export from the Pseudomonas periplasm; meropenem-vaborbactam is inactive because vaborbactam does not inhibit MexAB-OprM, allowing meropenem to be effluxed before PBP binding
ANSWER: D
Rationale:
The differential susceptibility between imipenem-relebactam and meropenem-vaborbactam in this Pseudomonas isolate reflects important differences in clinical data and the established role of relebactam in AmpC-mediated Pseudomonas resistance. Relebactam is a diazabicyclooctane (DBO) inhibitor that inhibits class A serine beta-lactamases (KPC) and class C AmpC cephalosporinases. Pseudomonas aeruginosa possesses a chromosomally encoded AmpC (PDC, Pseudomonas-derived cephalosporinase) that when overexpressed (through loss of its negative regulator) contributes to carbapenem resistance in combination with OprD porin loss. Relebactam's AmpC inhibitory activity reduces PDC-mediated hydrolysis of imipenem in the periplasm, allowing sufficient intact imipenem to accumulate for PBP engagement. While vaborbactam also inhibits class C AmpC enzymes, imipenem-relebactam has specifically demonstrated clinical and microbiological activity against multidrug-resistant and difficult-to-treat Pseudomonas aeruginosa (DTR-P. aeruginosa) in clinical data, including the RESTORE-IMI trial, while meropenem-vaborbactam has less established evidence in this Pseudomonas context.
Option A: Option A is incorrect; relebactam does not modulate OprD porin synthesis or expression — it is a serine beta-lactamase enzyme inhibitor with no gene regulatory activity.
Option B: Option B is incorrect; imipenem and meropenem have broadly similar PBP2 affinities in Pseudomonas; differential PBP2 binding affinity alone does not explain the susceptibility difference, and this framing ignores the role of the inhibitor components.
Option C: Option C is incorrect; Pseudomonas AmpC (PDC) is a class C serine enzyme, not a zinc-containing metalloenzyme; relebactam inhibits it through serine carbamylation, not zinc chelation, which is not a property of relebactam.
Option E: Option E is incorrect; relebactam does not inhibit MexAB-OprM or any efflux pump — it is a serine beta-lactamase inhibitor; efflux pump inhibition is not its mechanism of action.
12. A 38-year-old woman with a well-documented history of anaphylaxis to ampicillin (confirmed by allergist with positive skin test to penicilloyl-polylysine) requires antibiotic therapy for gram-negative bacteremia. The team considers aztreonam. A medical student asks whether aztreonam's beta-lactam ring creates cross-reactivity risk with penicillins. Integrating aztreonam's ring structure with the immunological basis of penicillin allergy, which of the following best explains why aztreonam can be safely administered to this patient?
A) Penicillin allergy is mediated by IgE sensitization to the penicilloyl major determinant — an epitope generated from the bicyclic beta-lactam-thiazolidine ring system of penicillin when the ring opens and forms a covalent protein adduct; aztreonam is a monobactam containing only a single unfused beta-lactam ring without the bicyclic thiazolidine component, so the immunogenic bicyclic epitopes of penicillin are structurally absent from aztreonam, producing negligible cross-reactivity
B) Penicillin allergy and aztreonam cross-reactivity both depend on the molecular weight of the drug-protein conjugate; because aztreonam forms a smaller hapten-protein conjugate than penicillin due to its lower molecular weight, IgE antibodies generated against the penicillin conjugate do not recognize the smaller aztreonam conjugate, producing apparent but structurally based cross-reactivity avoidance
C) Aztreonam's beta-lactam ring is in the D-configuration rather than the L-configuration found in penicillins; penicillin-specific IgE antibodies are stereoselective and do not recognize the D-configured beta-lactam ring of aztreonam, eliminating cross-reactivity through stereochemical discrimination
D) Aztreonam shares the identical R1 side chain as ceftazidime, not ampicillin, and because this patient's IgE was generated against the ampicillin R1 side chain specifically, aztreonam does not cross-react; the relevant cross-reactivity concern is between aztreonam and ceftazidime in patients sensitized to ceftazidime's R1 side chain, not between aztreonam and ampicillin
E) Aztreonam cannot form a stable covalent adduct with plasma proteins because its sulfonic acid group on the monocyclic nitrogen sterically blocks the reactive carbonyl carbon; without protein conjugate formation, no haptenization occurs and IgE sensitization is impossible regardless of prior penicillin exposure
ANSWER: A
Rationale:
Penicillin allergy at the IgE-mediated (immediate hypersensitivity) level is principally driven by the penicilloyl major determinant — the antigenic epitope formed when the strained bicyclic beta-lactam-thiazolidine ring of penicillin undergoes ring opening and the reactive carbonyl acylates lysine residues on plasma proteins, generating a stable penicilloyl-protein conjugate that stimulates IgE production. The structural requirement for this immunogenic pathway is the bicyclic ring system: the thiazolidine ring fused to the beta-lactam provides the specific geometry and breakdown product structure that is recognized by penicillin-specific IgE antibodies. Aztreonam, as the sole monobactam in clinical use, has a fundamentally different architecture: a single, unfused beta-lactam ring with no fused bicyclic component. The thiazolidine ring of penicillins is entirely absent; the degradation products of aztreonam do not generate the penicilloyl epitope or related bicyclic determinants. Clinical data consistently demonstrate negligible cross-reactivity between aztreonam and penicillins in penicillin-allergic patients, and aztreonam is considered safe for administration to patients with confirmed IgE-mediated penicillin allergy. Importantly, a separate cross-reactivity concern does exist between aztreonam and ceftazidime (they share an identical R1 aminothiazole side chain), but this is distinct from penicillin cross-reactivity.
Option B: Option B is incorrect; molecular weight of the hapten-protein conjugate is not the mechanism by which cross-reactivity is avoided; the structural absence of the bicyclic epitope is the correct explanation.
Option C: Option C is incorrect; beta-lactam ring stereochemistry (D vs L configuration) is not the immunological basis for absence of cross-reactivity; both penicillin and aztreonam beta-lactam rings share similar stereochemistry, and the absence of the bicyclic thiazolidine is the key structural difference.
Option D: Option D is incorrect in its framing as the primary explanation; while aztreonam's R1 side chain difference from ampicillin is accurate, the principal mechanistic reason for safe use in penicillin-allergic patients is the absence of the bicyclic ring epitopes, not R1 side chain mismatch; the option incompletely explains the mechanism.
Option E: Option E is incorrect; aztreonam does form protein conjugates and can cause allergic reactions — it simply does not generate the penicilloyl major determinant epitope; the sulfonic acid group does not block carbonyl reactivity in the manner described.
13. An infectious disease consultant discusses definitive therapy for CRE bacteremia with a resident, emphasizing that carbapenemase genotype — not just phenotypic susceptibility testing — must guide agent selection. Integrating the inhibitor spectra of ceftazidime-avibactam, meropenem-vaborbactam, and aztreonam-avibactam with the major carbapenemase classes, which of the following correctly maps genotype to preferred agent for three distinct CRE scenarios?
A) KPC-CRE → aztreonam-avibactam (because avibactam inhibits KPC while aztreonam provides the beta-lactam activity); NDM-CRE → ceftazidime-avibactam (because ceftazidime is NDM-stable and avibactam protects it from co-produced serine enzymes); OXA-48-CRE → meropenem-vaborbactam (because vaborbactam specifically targets OXA-48 class D enzymes)
B) KPC-CRE → ceftazidime-avibactam or meropenem-vaborbactam (both avibactam and vaborbactam inhibit KPC, a class A serine carbapenemase); NDM-CRE → aztreonam-avibactam (aztreonam is intrinsically NDM-stable, and avibactam inhibits co-produced serine enzymes); OXA-48-CRE → ceftazidime-avibactam preferred over meropenem-vaborbactam (avibactam inhibits OXA-48, a class D serine enzyme; vaborbactam's OXA-48 activity is limited)
C) KPC-CRE → meropenem-vaborbactam only (vaborbactam is the only inhibitor that achieves complete KPC inactivation; avibactam forms only partial inhibition of KPC at clinical concentrations); NDM-CRE → cefiderocol monotherapy (because cefiderocol's siderophore uptake bypasses NDM resistance entirely); OXA-48-CRE → imipenem-relebactam (relebactam is the only approved inhibitor with class D OXA-48 activity)
D) KPC-CRE → ceftazidime-avibactam only (vaborbactam does not inhibit KPC because boronic acid inhibitors cannot achieve adequate periplasmic concentrations in KPC-producing strains with porin loss); NDM-CRE → meropenem-vaborbactam in combination with aztreonam (meropenem provides synergy against NDM because its C-2 side chain slows NDM-mediated hydrolysis); OXA-48-CRE → aztreonam-avibactam
E) KPC-CRE → imipenem-relebactam only because relebactam achieves the highest periplasmic KPC inhibition of all approved DBO inhibitors; NDM-CRE → ceftazidime-avibactam (avibactam partially inhibits NDM at the elevated concentrations used for CRE therapy); OXA-48-CRE → meropenem-vaborbactam (vaborbactam's class D activity is superior to avibactam for OXA-48)
ANSWER: B
Rationale:
The genotype-first approach to CRE therapy is essential because the three approved novel combinations have distinct and non-overlapping carbapenemase inhibitory spectra that determine clinical efficacy. For KPC-CRE: KPC is a class A serine carbapenemase inhibited by both avibactam (a DBO inhibitor) and vaborbactam (a boronic acid inhibitor); ceftazidime-avibactam and meropenem-vaborbactam are both appropriate options, with choice guided by institutional availability, drug interaction profile, and individual patient factors. For NDM-CRE: NDM is a class B zinc-dependent metallo-beta-lactamase that is not inhibited by avibactam, vaborbactam, or relebactam (all serine-targeting inhibitors); aztreonam-avibactam exploits aztreonam's intrinsic NDM stability combined with avibactam's inhibition of co-produced serine beta-lactamases (ESBL, AmpC, KPC) that would otherwise hydrolyze aztreonam. For OXA-48-CRE: OXA-48 is a class D serine carbapenemase inhibited by avibactam but not reliably by vaborbactam; ceftazidime-avibactam is therefore preferred over meropenem-vaborbactam for confirmed OXA-48-CRE. This genotype-to-therapy mapping is the clinical standard requiring carbapenemase PCR or molecular testing before finalizing definitive therapy.
Option A: Option A is incorrect; the assignments are scrambled — KPC-CRE should not be treated with aztreonam-avibactam as the preferred agent (ceftazidime-avibactam or meropenem-vaborbactam are the standard KPC regimens); NDM-CRE is not treated with ceftazidime-avibactam; and OXA-48-CRE is not treated with meropenem-vaborbactam preferentially.
Option C: Option C is incorrect; both avibactam and vaborbactam adequately inhibit KPC at clinical concentrations — the claim that avibactam achieves only partial KPC inhibition is false; cefiderocol monotherapy is not the guideline-preferred agent for NDM-CRE; and relebactam is not established as the primary agent for OXA-48-CRE.
Option D: Option D is incorrect; vaborbactam does achieve adequate KPC inhibition; the claim that porin loss prevents vaborbactam from reaching periplasmic KPC is not the established mechanism distinguishing these agents; meropenem does not "slow" NDM hydrolysis through its C-2 side chain — it is hydrolyzed by NDM.
Option E: Option E is incorrect; avibactam does not partially inhibit NDM at any clinical concentration — this is mechanistically impossible; and vaborbactam does not have superior OXA-48 class D activity compared to avibactam; avibactam covers OXA-48 more reliably than vaborbactam.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.